The FDA has approved Zusduri (mitomycin intravesical solution) to treat adults with recurrent, low-grade, intermediate-risk NMIBC.

Keytruda (pembrolizumab) is now approved as perioperative treatment for patients with head and neck squamous cell carcinoma.

The US Food and Drug Administration (FDA) has approved a new tablet formulation of Brukinsa (zanubrutinib), which is expected to replace the current capsule formulation in October 2025. Brukinsa, a ...

Workers at the NIH sent a letter protesting the Trump administration’s cuts to the agency's budget, staff, and research.

The FDA has granted fast track designation to nadunolimab for use in combination with gemcitabine and nab-paclitaxel to treat patients with previously untreated, metastatic PDAC with high IL1RAP ...

HHS Secretary Robert F. Kennedy Jr has named 8 new members to the CDC’s Advisory Committee on Immunization Practices.

Combining TTFields with gemcitabine and nab-paclitaxel can improve OS in patients with locally advanced pancreatic adenocarcinoma, results of the PANOVA-3 trial suggest.

The Clinical Advisor spoke with Carlos Gutiérrez, EdD, MMS, PA-C, about the impact of executive orders on LGBTQ+ health care.

The FDA has accepted the application for lurbinectedin in combination with atezolizumab as first-line maintenance for ES-SCLC.

The FDA has granted de novo authorization to CLAIRITY BREAST, a platform that uses AI to help predict a woman's risk of breast cancer.

Study results highlight the need to improve adverse event cost quantification in oncology cost-effectiveness analyses, researchers say.

Nivolumab plus ipilimumab did not improve OS vs chemotherapy in patients with previously untreated, unresectable/metastatic urothelial carcinoma.